By Bhanvi Satija LONDON, Jan 22 (Reuters) - Sweeping U.S. policy changes under Health Secretary Robert F. Kennedy Jr. are ...

By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...

Earlier in January 2026, Novavax announced a non-exclusive license and option agreement granting Pfizer worldwide rights to ...

In the latest close session, Novavax (NVAX) was down 1.97% at $9.71. This change lagged the S&P 500's 0.55% gain on the day.

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 19.7% in the afternoon session after the company ...

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...

Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to ...

Gaithersburg’s Novavax has struck a deal to give Pfizer the rights to its adjuvant technology — for a potential $530 million ...

Novavax shares are trading higher Tuesday after the company announced it entered into a license agreement with Pfizer for ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Shares of US biotech Novavax were up 9% at $8.72 by midday on Tuesday, after it revealed it has entered into a license ...